Summary
Blockade of the CD80/86-CD28 pathway by belatacept after kidney transplantation is associated with an increased risk of rejection compared with standard, calcineurin inhibitor (CNI)-based therapy. CD28 -T cells, which express CD57, are not susceptible to belatacept treatment. High numbers of CD4 
PD-1 -T cells (median of inhibition 10%,

Introduction
Belatacept is an immunosuppressive agent used in kidney transplantation as an alternative to calcineurin inhibitor (CNI) therapy [1, 2] . Studies have shown that long-term kidney allograft function and survival is improved in belatacept-treated patients compared to patients treated with the CNI cyclosporin [3] [4] [5] . Belatacept exerts its immunosuppressive effect through a different mechanism to CNIs: it binds to CD80/86 (B7-1/2) on antigenpresenting cells, thereby blocking the CD28-mediated costimulatory signal on naive T cells. Immune activation of CD28 1 T cells via T cell receptors without a co-stimulatory signal during belatacept treatment results in anergy [6, 7] . However, antigen-experienced T cells down-regulate CD28 [8] and are therefore able to escape co-stimulatory blockade by belatacept [9, 10] . It has been hypothesized that these CD28 -memory T cells are responsible for the increased rejection risk of patients treated with belatacept [11, 12] . The vast majority of these CD28 -cells express CD57, a marker expressed by natural killer (NK) cells and T cells [13] which is used to identify terminally differentiated senescent cells with reduced proliferative capacity [14] . This marker, also known as human natural killer-1 (HNK-1), is associated with cell-cell and/or cell-matrix interactions and is also correlated with end-stage renal disease and cytomegalovirus (CMV) infection [15] [16] [17] [18] [19] .
In a recent study [20] , a high percentage of CD4
2 T cells was identified as a biomarker to predict belatacept-resistant rejection (BRR) in a small cohort of kidney transplant patients. PD-1 is a negative co-stimulatory member of the CD28 family which is up-regulated upon T cell activation. These authors also demonstrated that, after polyclonal stimulation, CD4 1 CD57 1 PD-1 -T cells produced high levels of the effector cytokines interferon (IFN)-g or tumour necrosis factor (TNF)-a, or exhibited cytotoxicity [20] . CD4
1
CD57
1 T cells were also found to infiltrate the kidney allograft during rejection, and genes involved in allograft rejection were up-regulated in this T cell subset [20] . However, these findings were not confirmed in recent randomized controlled clinical trials in which belataceptbased immunosuppressive therapy was compared with tacrolimus-based immunosuppressive therapy [21] [22] [23] . In the study by de Graav et al., 11 of the 20 (55%) belatacepttreated patients experienced biopsy-proven acute rejection (BPAR) compared with two of 20 in the control arm [12, 23] , while in another study patient enrolment was even halted because of a high rate of acute cellular rejection [21] . In the study by de Graav et al. [23] , no association between rejection and higher frequencies of CD4
1
CD57
1 PD-1 -was found. Therefore, it is currently unclear whether the proportion of CD4 1 CD57 1 PD-1 -T cells prior to kidney transplantation is a robust predictor of rejection in belatacept-treated patients.
When activated, T cells up-regulate different costimulatory receptors, such as PD-1, CD223 and CD244, on their cell surface [24] [25] [26] (Fig. 1) .
This series of experiments was undertaken because conflicting reports were found in the literature regarding the predictive value of CD4
1 CD57 1 PD-1 -in kidney transplant patients as a predictor of belatacept resistant rejection. It was expected that this T cell subtype could evade belatacept treatment, as CD57
1 T cells express low amounts of CD28 [18, 19] . This hypothesis was based on findings from a study which described the function of this cell population in healthy controls [20] , showing that CD57
1 T cells exhibit a genetic profile associated closely with allograft rejection signalling. To understand more clearly the contribution made by CD57 1 T cells to rejection, and their potential influence on rejection prophylaxis by belatacept, we investigated the effect of allogeneic stimulation on CD57 1 T cell subsets in the presence and absence of belatacept using cells from kidney transplant patients who received belatacept-based immunosuppression. We also assessed the alloreactivity of CD4 1 CD57 1 PD-1 -T cells in terms of cytotoxic and co-inhibitory properties.
Material and methods
Patients and study design
The study population consisted of 20 kidney transplant recipients who were treated with belatacept as part of a randomized controlled clinical trial [17] . All patients received belatacept (Nulojix V R ; Bristol Myers-Squibb, New York, NY, USA) according to the less intensive regimen [3] , in combination with basiliximab induction therapy (20 mg intravenously on days 0 and 4) and maintenance therapy with mycophenolate mofetil and prednisolone. Patients were eligible for participation when they were scheduled to receive a single blood group ABO-compatible kidney from a living donor. All former and current cross-match cytotoxicity tests were negative prior to transplantation. All patients gave written informed consent before inclusion. The study was performed according to good clinical practice (GCP) guidelines and the declaration of Istanbul [27] . The clinical study was registered at the Dutch national trial registry (http://www.trialregister.nl/trialreg.nl/index.asp; number NTR4242, October 2013) and was approved by the institutional review board of Erasmus MC (METC number 2012-421) [23] .
Isolation of peripheral blood mononuclear cells (PBMCs)
Prior to transplantation PBMCs were isolated from heparinized blood by density gradient centrifugation using FicollPaque (VWR, Amsterdam, the Netherlands), then frozen in supplemented RPMI-1640 1 glutamax (Fisher Scientific, Landsmeer, the Netherlands) with 10% fetal bovine serum (FBS) (Lonza, Verviers, Belgium) and 10% dimethyl sulphoxide (DMSO) (VWR) and stored at 21408C.
Mixed lymphocyte reaction and staining of fluorescence activated cell sorted (FACS) cells
A flowchart of the experimental design is given in Supporting information, Fig. S1 .
To establish cytotoxic function and co-inhibitory molecule expression, T cells were sorted by the FACS method. For this purpose, PBMCs from four patients and four healthy controls were thawed and stained for 30 min at room temperature. Different T cell subsets (
were selected using fluorescein isothiocyanate (FITC)-labelled anti-CD57 (BD Biosciences, Erembodegem, Belgium), allophycocyanin-cyanine 7 (APC-Cy7)-labelled anti-CD8a (Biolegend, London, UK), BV421-labelled anti-CD4 (Biolegend), BV51-labelled anti-CD3 (Biolegend) and phycoerythrin (PE)-labelled anti-PD-1 (Biolegend). Within these cells the expression of several co-inhibitory signals was examined, using peridinin chlorophyll (PerCP)-eFluor710-labelled anti-CD223 (eBioscience, Vienna, Austria) and PECy7(phycoerythrin-cyanine 7)-labelled anti-CD244 (Biolegend). The selected subsets were FACS-sorted using a Facs Aria 2 (BD Biosciences) with a purity of > 95%.
In order to be able to focus upon responder CD3 1 cells, a modified mixed lymphocyte reaction (MLR) was set up. Donor or healthy control PBMCs were thawed and depleted for CD3 1 T cells using magnetic separation with an AutoMacs (Miltenyi Biotec, Bergisch Gladbach, Germany) with a purity of > 90%. The isolated T cell subsets of the patients and healthy controls were co-cultured in a mixed lymphocyte reaction using 40 Gy-irradiated T celldepleted donor or randomized healthy control stimulator cells, respectively, at a concentration of 5 3 10 4 /well and 5 3 10 4 /well for 7 days in a 96-well plate. Cells were stained for CD3, CD4, CD8a, CD57, CD223, CD244 and PD-1 using the antibodies described above. Upon fixation and permeabilization using the forkhead box protein 3 (FoxP3)/transcription factor staining buffer set (eBioscience), cells were stained intracellularly using PE-CF594-labelled anti-granzyme-B (BD Biosciences) and Alexa700-labelled anti-Ki-67 (BD Biosciences). Expression of the co-inhibitory markers CD223, CD224 and PD-1 was determined by assessing percentages of positive cells. Proliferation was determined by gating the Ki-67-negative population. Granzyme B expression was determined by analysing the median fluorescence intensity (MFI) of the granzyme B signal. All samples were analysed using Kaluza software (Beckman Coulter, Woerden, the Netherlands)
Mixed lymphocyte reaction and intracellular staining with or without belatacept A flowchart of the experimental design is given in Supporting information, Fig. S2 .
To analyse the cytotoxic capacity of CD4 1 CD57 1 PD-1 -T cells, thawed PBMCs were seeded in 96-well plates at 5 3 10 4 cells per well, with or without added belatacept (10 mg/ml). After 1 h, 5 3 10 4 donor cells were added per well and co-cultured for 7 days. Thereafter, the cells were harvested and stained using flow cytometry. The cells were stained for 30 min at room temperature to test for viability using LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen, Paisley, UK). Subsequently, the cell surface was stained using FITC-labelled anti-CD57 (BD Biosciences), PE-labelled anti-PD-1 (Biolegend), APC-labelled anti-CD28 (BD Biosciences), Alexa700-labelled anti-CD3 (BD Biosciences), APC-eF780-labelled anti-CD8a (eBioscience), V450-labelled anti-CD4 (BD Biosciences), Pacific orangelabelled anti-CD14 (Invitrogen) and Pacific orange-labelled anti-CD20 (Invitrogen). The cells were fixed and permeabilized using the Cytofix/Cytoperm kit (BD Biosciences) and stained intracellularly using PE-CF594-labelled anti-granzyme-B (BD Biosciences). Samples were measured on a Navios flow cytometer (Beckman Coulter) and analysed using Kaluza software version 1.3 (Beckman Coulter). To emphasize the effect of belatacept on granzyme B expression we analysed granzyme B expression by analysing the MFI of the granzyme B signal. Granzyme B expression was normalized using the following formula:
MFI of MLR with belatacept MFI of MLR without belatacept
Statistical analysis
Statistical analyses were performed using GraphPad prism version 5.0.1 (GraphPad Software Inc., San Diego, CA, USA) software. Data were analysed using Wilcoxon's signed-rank test. P-values less than 0Á05 were considered statistically significant.
Results
Study population
The study population comprised 20 kidney transplant recipients, 11 of whom (55%) developed BPAR in the first year after transplantation. One of these patients could not be included into this study because of a too-low yield of biomaterial. Details of the clinical outcome of this study were described previously [23] . The key characteristics are summarized in Table 1 .
Functional analysis of isolated T cell populations
The effect of allogeneic stimulation on CD57 1 PD-1 -and CD57 -PD-1 -CD4 1 and CD8 1 T cells in terms of upregulation of co-inhibitory molecules, cell proliferation and cytotoxic potential was measured using FACS-isolated T cell populations (> 95% pure) from four kidney transplant recipients prior to transplantation and four healthy controls. Expression of the co-inhibitory receptors CD223 (Lag-3) and CD244 (2B4) before and after 7 days of alloantigen stimulation were studied, as well as up-regulation of the co-inhibitory marker PD-1. Figure 2a shows a typical example of the gating strategy used for sorting the four T cell subsets. After stimulation, these cells were analysed for expression levels of the co-inhibitory markers. An example of the CD4 1 subsets is shown in Fig. 2b . No CD223 expression was found on any of the studied populations before allogeneic stimulation, while these T cell subsets all up-regulated CD223 after alloantigen stimulation by approximately 7-15%, on average ( Fig. 2c, P < 0Á01) . The proportion of cells expressing CD223 was comparable between CD57 and CD57 -PD-1 -for both CD4 1 and CD8 1 T cells (Fig.  2c) . A different profile was found for CD244 (Fig. 2d) 
PD-1
-T cell population, CD244 expression was down-regulated after ) Expression of the co-inhibitory signals on sorted populations before and after 7 days of alloantigen stimulation in four patients prior to kidney transplantation (white dots) and four healthy controls (grey dots). For PD-1 only, upregulation was shown after 7 days of stimulation, as the starting populations were sorted to be PD-1
-(e). Expression is shown before and after stimulation and was tested with Wilcoxon's signed-rank test. Also, the difference in up-regulation between the CD57 1 and CD57 -subsets was compared with Wilcoxon's signed-rank test (*P < 0Á05; ** P < 0Á01). [Colour figure can be viewed at wileyonlinelibrary.com] alloantigen stimulation by approximately 32% (P < 0Á05). However, a large proportion (46%, mean) of these T cells still expressed CD244. CD4 1 CD57 -PD-1 -T cells expressed low amounts of CD244 prior to stimulation, but a marginal up-regulation of 7% was seen after stimulation (P < 0Á01). CD244 expression was down-regulated within CD8
1 CD57 -PD-1 -T cells by approximately 16% (P < 0Á05). A significant difference in CD244 upregulation was found between the two CD4 1 T cell subsets (P < 0Á05). Up-regulation of PD-1 expression after alloantigen stimulation (Fig. 2e) (6 20%) , while the other three T cell subsets did not (Fig. 3a,b) . When CD57 (Fig. 3a,c) . 
Effect of belatacept on cytotoxicity of PBMC
On day 0 (i.e. before allogeneic stimulation) CD28 expression was found predominantly on CD57 -PD-1 -CD4 1 and CD8 1 T cells (Fig. 4a,b) . Interestingly, although all CD4 1
CD57
-PD-1 -T cells expressed CD28, only 50% of the CD8
1 CD57 -PD-1 -T cells expressed this indirect target for belatacept. The expression of CD57 after 1 week of culture did not differ from the initial sorted populations (Fig. 4c) . CD4 1 CD57 1 T cells are a rare cell population, and only a limited number of experiments could be performed. Because the expression of CD57 did not change after 7 days of stimulation (Fig. 4c) and because of low cell numbers the inhibitory effect of belatacept was tested instead on PBMCs. The experimental design of these experiments is illustrated in Supporting information, Fig. S2 . A typical example of the effect of belatacept on granzyme B protein expression is shown in Fig. 5a . Figure 5b shows the inhibition of granzyme B expression by belatacept. Patients were arranged according to inhibition of granzyme B. Granzyme B expression after alloantigen stimulation was inhibited significantly in the presence of belatacept for CD4
1
CD57
1 PD-1 -T cells by 31% (P < 0Á01, top left panel) and for CD8
1 CD57 1 PD-1 -by 10% (P < 0Á05, bottom left panel), and for both CD57 -CD4 1 and CD8 1 T cells by 30 and 42%, respectively (both P < 0Á001, right panel) (Fig. 5b) . Wilcoxon's signed-rank test (*P < 0Á05; **P < 0Á01). [Colour figure can be viewed at wileyonlinelibrary.com]
To determine whether T cells from patients with or without BPAR (i.e. rejectors and non-rejectors) respond differently to co-stimulation blockade, the expression of granzyme B in the CD4 1 and CD8 1 T cell subsets was compared between these two patient groups. In-vitro studies showed comparable inhibition by belatacept of granzyme B expression for all T cell subsets studied, regardless of whether or not the patient experienced BPAR (Fig. 5b) .
Discussion
The predictive value of CD4 [30] . Recent studies have suggested that CD244 expression on T cells can be used as an indicator for CD28 null T cells [31, 32] . This could be attributed to the fact that T cells which naturally down-regulate CD28 in response to chronic infections and ageing are associated with expression of NK receptors [33, 34] . On a functional level, the separation between CD57 [17] . Most of the patients used for these sortings were also CMV-positive, which also increases the frequency of this subset. While our results show interesting distinctive properties of the different T cell populations, it is of importance to consider the limitations of this study. No specific inclusion and exclusion criteria were implemented in our study protocol; PBMC samples were analysed when enough recipient PBMCs and donor cells were available for FACS sorting and further functional analysis. We used a combined amount of four healthy control and four patient samples to study the function of a rare CD4 1 CD57 1 T cell population. However, the expression of CD57 did not change after 7 days of stimulation, therefore we decided to continue the rest of our experiments with unsorted PBMCs to allow for analysis of the effect of belatacept on granzyme B expression after allogeneic stimulation of 19 patients to test if belatacept has an inhibitory effect on the different subsets, as this could explain why CD4 1 CD57 1 PD-1 -could be a potential biomarker for belatacept-resistant rejection. As CD57 1 T cells are mainly CD28 - [13] and thus not susceptible (or less susceptible) to belatacept blockade, we hypothesized that in contrast to CD57 -, co-stimulation blockade would not control the function of CD57 1 T cells. Surprisingly, the in-vitro study showed that the potentially cytolytic functions of CD57 1 T cells were also affected by bela- demonstrated recently that up-and down-regulation of CD28 is a dynamic process in alloantigen-stimulated T cells [9] . This might explain the inhibition of granzyme B expression by belatacept within CD4 1 CD57 1 PD-1 -T cells. In conclusion, this study shows that CD4
1 CD57 1 PD-1 -T cells have less proliferative capacity but a more cytotoxic profile than their CD57 -counterparts, suggesting that these are terminally differentiated cells. In spite of this, alloantigen-triggered cytotoxicity can be inhibited partly by belatacept, and was not found to be associated with the development of rejection in patients after kidney transplantation.
Supporting information
Additional Supporting information may be found in the online version of this article at the publisher's web-site: Fig. S1 . Mechanistic analysis. This flowchart shows the experimental design of our first experiment in which we sorted four T cell subsets to stimulate them with alloantigen. Fig. S2 . Inhibition of granzyme B expression by belatacept. This flowchart shows the experimental set-up of our second experiment in which we stimulated patient peripheral blood mononuclear cells (PBMCs) and stimulated them with alloantigen in the presence or absence of belatacept to examine the cytotoxic capacity after 7 days.
